Salute e Benessere
MolecuLight Secures $11.7 Million in Financing to Accelerate Global Expansion
"MolecuLight's innovative technology has the potential to significantly improve patient outcomes and offers compelling benefits for all healthcare system stakeholders," said Guillermo Freire , Senior Vice-President, Mid-Market Group, EDC. "We are excited to invest in MolecuLight as they accelerate commercialization. EDC is focused on supporting emerging Canadian innovators in critical sectors essential for the future. This investment reflects our belief in innovation and progress, underscoring mission is to support Canadian companies in their journey to become international leaders in their sectors."
"We are pleased to invest in MolecuLight. We believe in MolecuLight's mission to transform wound care and with their innovative technology," said Azahar. "This investment will enable MolecuLight to accelerate its expansion efforts to more healthcare providers worldwide."
"iGan is proud to continue supporting MolecuLight on their journey to transform the management of wound care," said Sam Ifergan , Chairman of MolecuLight and Managing Director at iGan Partners.
"This financing is a testament to MolecuLight's strong market position and the significant impact our technology is having on patient care," said Anil Amlani, CEO of MolecuLight. "With the support of our investors, we are well-positioned to capitalize on the growing demand for point-of-care fluorescence imaging solutions and deliver exceptional value to our customers."
Tungsten Advisors served as the exclusive financial advisor to MolecuLight.
MolecuLight is the leader in in point-of-care fluorescence imaging. Their innovative devices empower healthcare providers to quickly and accurately detect elevated levels of bacteria in wounds, surgical sites, and other injuries. This real-time visualization of bacteria that is linked to infection empowers clinicians to make informed treatment decisions. Early and accurate detection of bacteria leads to more targeted treatment plans. By optimizing treatment plans, MolecuLight technology helps to accelerate healing and reduce the risk of complications. The multi-modal device combines bacterial detection, wound measurement, and imaging capabilities into a single tool, streamlining workflows and improving documentation accuracy. Integrating seamlessly with electronic medical records, MolecuLight empowers clinicians to deliver the highest standard of care while optimizing their workflow. For more information, please visit www.moleculight.com.
For more information, contact: Hunter Zudans , Director of Marketing, MolecuLight Inc., T. +1.484.682.7580, hzudans@moleculight.com
Photo - https://mma.prnewswire.com/media/2482399/MolecuLight_MolecuLight_Secures__11_7_Million_in_Financing_to_Ac.jpg
View original content:https://www.prnewswire.co.uk/news-releases/moleculight-secures-11-7-million-in-financing-to-accelerate-global-expansion-302222745.html